Barclays Maintains Overweight on Elevance Health, Raises Price Target to $408

Benzinga Newsdesk www.benzinga.com Positive 82.2%

Neg 0% Neu 0% Pos 82.2%

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $393 to $408.